Login to Your Account



Second Try By Oracle Succeeds

Precision Therapeutics' IPO Set Aside; Merger Planned

By Randall Osborne


Monday, December 10, 2007
Precision Therapeutics Inc.'s move to go public by way of a reverse merger with a special-purpose acquisition firm gives a boost to marketing of its ChemoFx test, which uses a patient's live tumor cells to measure the likelihood of response to cancer drugs. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription